Type 2 diabetes and obesity in midlife and breast cancer risk in the Reykjavik cohort
As obesity and type 2 diabetes (T2D) have been increasing worldwide, we investigated their association with breast cancer incidence in the Reykjavik Study.
During 1968–1996, approximately 10,000 women (mean age = 53 ± 9 years) completed questionnaires and donated blood samples. T2D status was classified according to self-report (n = 140) and glucose levels (n = 154) at cohort entry. A linkage with the Icelandic Cancer Registry provided breast cancer incidence through 2015. Cox regression with age as time metric and adjusted for known confounders was applied to obtain hazard ratios (HR) and 95% confidence intervals (CI).
Of 9,606 participants, 294 (3.1%) were classified as T2D cases at cohort entry while 728 (7.8%) women were diagnosed with breast cancer during 28.4 ± 11.6 years of follow-up. No significant association of T2D (HR 0.95; 95% CI 0.56–1.53) with breast cancer incidence was detected except among the small number of women with advanced breast cancer (HR 3.30; 95% CI 1.13–9.62). Breast cancer incidence was elevated among overweight/obese women without (HR 1.18; 95% CI 1.01–1.37) and with T2D (HR 1.35; 95% CI 0.79–2.31). Height also predicted higher breast cancer incidence (HR 1.03; 95% CI 1.02–1.05). All findings were confirmed in women of the AGES–Reykjavik sub-cohort (n = 3,103) who returned for an exam during 2002–2006. With a 10% T2D prevalence and 93 incident breast cancer cases, the HR for T2D was 1.18 (95% CI 0.62–2.27).
These findings in a population with low T2D incidence suggest that the presence of T2D does not confer additional breast cancer risk and confirm the importance of height and excess body weight as breast cancer risk factors.
KeywordsBreast cancer Type 2 diabetes Obesity Anthropometry Prospective cohort Cox regression
The AGES–Reykjavik Study was funded by NIH contract N01-AG-12100, the Intramural Research Program of the National Institute on Aging, the Icelandic Heart Association, and the Icelandic Parliament. This work was also supported by the Icelandic Centre for Research, RANNIS Grant Number: 152495051, https://en.rannis.is/ (to AH), and the Public Health Fund of the Icelandic Directorate of Health (to AH). GM was funded by a Fulbright Global Scholar Award (2017–2018).
- 1.International Diabetes Federation (2017) IDF Diabetes Atlas 2017. https://www.diabetesatlas.org/. Accessed 21 Jun 2018.
- 2.Maskarinec G, Grandinetti A, Matsuura G et al (2009) Diabetes prevalence and body mass index differ by ethnicity: the Multiethnic Cohort. Ethn Dis 19:49–55Google Scholar
- 4.Parkin DM, Boyd L, Walker LC (2011) The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer 105(Suppl 2): S77–S81Google Scholar
- 19.Olafsdottir E, Aspelund T, Sigurdsson G et al (2009) Unfavourable risk factors for type 2 diabetes mellitus are already apparent more than a decade before onset in a population-based study of older persons: from the Age, Gene/Environment Susceptibility-Reykjavik Study (AGES-Reykjavik). Eur J Epidemiol 24:307–314CrossRefGoogle Scholar
- 21.World Health Organization (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. https://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf. Accessed 6 Mar 2018
- 32.Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015 (2017) Lancet 390: 231–266Google Scholar
- 35.Bergsveinsson J, Aspelund T, Gudnason V, Benediktsson R (2007) Prevalence of type 2 diabetes mellitus in Iceland 1967–2002. Laeknabladid 93:397–402Google Scholar